BCAL Diagnostics Limited (ASX:BDX)

Australia flag Australia · Delayed Price · Currency is AUD
0.0800
0.00 (0.00%)
Apr 28, 2026, 10:17 AM AEST
-4.76%
Market Cap 29.49M
Revenue (ttm) 2.54M
Net Income (ttm) -7.16M
Shares Out 368.68M
EPS (ttm) -0.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 71,604
Average Volume 112,635
Open 0.0800
Previous Close 0.0800
Day's Range 0.0800 - 0.0800
52-Week Range 0.0520 - 0.1550
Beta 0.89
RSI 33.92
Earnings Date May 18, 2026

About BCAL Diagnostics

BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a novel blood screening test to improve the diagnosis and monitoring of breast cancer. It develops BREASTESTplus, a first-in-class blood test designed to be used alongside standard mammogram in breast cancer screening. The company also develops BREASTEST, BCAL Diagnostics, and BCAL Dx. The company was incorporated in 2010 and is headquartered in Sydney, Australia. [Read more]

Sector Healthcare
Founded 2010
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol BDX
Full Company Profile

Financial Performance

In fiscal year 2025, BCAL Diagnostics's revenue was 2.65 million, a decrease of -13.01% compared to the previous year's 3.05 million. Losses were -7.24 million, 13.1% more than in 2024.

Financial Statements

News

There is no news available yet.